Karyopharm's myelofibrosis drug trial meets one of two primary goals

March 24, 2026 7:01 AM

Karyopharm Therapeutics Inc. (NASDAQ: KPTI) announced that its Phase 3 SENTRY trial of selinexor combined with ruxolitinib in myelofibrosis patients ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found